Paper-based lateral flow assays (LFAs) are among the most widely used biosensing platforms for point-of-care testing (POCT). However, the conventional colloidal gold label of LFAs show low sensitivity and limited quantitative capacity. Alternatively, the use of enzyme/chemical reaction-based signal amplification with structural modifications has enhanced analytical capacity but requires multiple user interventions as a trade-off, increasing complexity, test imprecision, and time. These platforms are also difficult to manufacture, limiting their practical applications. In this study, within the current LFA production framework, we developed a highly sensitive, automated, universal, and manufacturable LFA biosensing platform by (i) incorporating gold nanoparticles into a polymer-networked peroxidase with an antibody as a new scheme for enhanced enzyme conjugation and (ii) integrating a mass-producible and time-programmable amplification part based on a water-swellable polymer for automating the sequential reactions in the immunoassay and signal amplification, without compromising performance, simplicity, and production feasibility. We applied this platform to evaluate cardiac troponin I (cTnI), a gold-standard biomarker for myocardial infarction diagnosis. Quantitative analysis of cTnI in clinical setting remains limited to the laboratory-based high-end and costly standard equipment. Coupled with an enzymecatalyzed chemiluminescence method, this platform enables automated, cost-effective (0.66 USD per test), and highperformance testing of human cTnI in serum samples within 20 min with a detection range of 6 orders of magnitude, detection limit of 0.84 pg mL −1 (595-fold higher than conventional cTnI-LFA), and a coefficient of variation of 2.9−8.5%, which are comparable to the standard equipment and acceptable for clinical use. Moreover, cTnI analysis results using clinical serum/ plasma samples revealed a strong correlation (R 2 = 0.991) with contemporary standard equipment, demonstrating the practical application of this platform for high-performance POCT.
As
a global shift continues to occur in high burden diseases toward
developing countries, the importance of medical diagnostics based
on point-of-care testing (POCT) is rapidly increasing. However, most
diagnostic tests that meet clinical standards rely on high-end analyzers
in central hospitals. Here, we report the development of a simple,
low-cost, mass-producible, highly sensitive/quantitative, automated,
and robust paper/soluble polymer hybrid-based lateral flow biosensing
platform, paired with a smartphone-based reader, for high-performance
POCT. The testing architecture incorporates a polymeric barrier that
programs/automates sequential reactions via a polymer dissolving mechanism.
The smartphone-based reader with simple opto-mechanical parts offers
a stable framework for accurate quantification. Analytical performance
of this platform was evaluated by testing human cardiac troponin I
(cTnI), a preferred biomarker for the diagnosis of myocardial infarction,
in serum/plasma samples. Coupled with catalytic/colorimetric gold-ion
amplification, this platform produced results within 20 min with a
detection limit of 0.92 pg mL–1 and a coefficient
of variation <10%, which is equivalent to the performance of a
high-sensitivity standard analyzer, and operated within acceptable
levels stipulated by clinical guidelines. Moreover, cTnI clinical
sample tests indicate a high correlation (r = 0.981)
with the contemporary analyzers, demonstrating the clinical utility
of this platform in high-performance POCT.
Diabetes mellitus is one of the most
common chronic diseases worldwide.
Generally, the levels of fasting or postprandial blood glucose and
other biomarkers, such as glycated albumin, glycated hemoglobin, and
1,5-anhydroglucitol, are used to diagnose or monitor diabetes progression.
In the present study, we developed a sensor to simultaneously detect
the glucose levels and glycation ratios of human serum albumin using
a lateral flow assay. Based on the specific enzymatic reactions and
immunoassays, a spiked glucose solution, total human serum albumin,
and glycated albumin were measured simultaneously. To test the performance
of the developed sensor, clinical serum samples from healthy subjects
and patients with diabetes were analyzed. The glucose level and glycation
ratios of the clinical samples were determined with reasonable correlation.
The R-squared values of glucose level and glycation
ratio measurements were 0.932 and 0.930, respectively. The average
detection recoveries of the sensor were 85.80% for glucose and 98.32%
for the glycation ratio. The glucose level and glycation ratio in
our results were crosschecked with reference diagnostic values of
diabetes. Based on the outcomes of the present study, we propose that
this novel platform can be utilized for the simultaneous detection
of glucose and glycation ratios to diagnose and monitor diabetes mellitus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.